Free Trial
→ Elon’s Secret Social Security Bombshell (From Banyan Hill Publishing) (Ad)tc pixel

ImmuPharma (LON:IMM) Trading 28.6% Higher - Here's Why

Written by MarketBeat
September 30, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's stock surged 28.6% to a last trading price of GBX 11.30 ($0.15) on high trading volume of over 17 million shares, significantly exceeding its average session volume.
  • The company has a market cap of £56.47 million and reported negative earnings per share of GBX (0.38) in its last quarterly earnings, with an anticipated fiscal year EPS of approximately -339.
  • ImmuPharma specializes in developing peptide-based therapeutics, with its lead program, Lupuzor™, targeting autoimmune diseases like Lupus.
  • Five stocks to consider instead of ImmuPharma.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded up 28.6% on Tuesday . The stock traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). 17,007,168 shares were traded during trading, an increase of 97% from the average session volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Stock Up 28.6%

The stock has a market cap of £56.47 million, a price-to-earnings ratio of -1,269.66 and a beta of 1.53. The firm's 50 day moving average is GBX 5.30 and its two-hundred day moving average is GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.